13398-55-5

Upstream product

• 208938-35-6 (S)-3-(tert-Butyl-dimethyl-silanyloxy)-2-methyl-2-phenyl-propionic acid 
• 208938-33-4 (S)-3-(tert-Butyl-dimethyl-silanyloxy)-2-methyl-2-phenyl-propionaldehyde 
• 208938-37-8 tert-Butyl-((S)-2-isocyanato-2-phenyl-propoxy)-dimethyl-silane 

Downstream Products

• 208938-45-8 ((S)-2-Hydroxy-1-methyl-1-phenyl-ethyl)-carbamic acid tert-butyl ester 
• 802541-88-4 N-(tert-butoxycarbonyl)-2-phenyl-D-alanine 

Relevant academic research and scientific papers

3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH

The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formula (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer.

3-PYRIMIDIN-4-YL-OXAZOLIDIN-2-ONES AS INHIBITORS OF MUTANT IDH

The invention is directed to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1-R6 are defined herein. The invention is also directed to compositions containing a compound of formula (I) and to the use of such compounds in the inhibition of mutant IDH proteins having a neomorphic activity. The invention is further directed to the use of a compound of formual (I) in the treatment of diseases or disorders associated with such mutant IDH proteins including, but not limited to, cell-proliferation disorders, such as cancer

Asymmetric synthesis of α,α-disubstituted α-amino acide derivatives using MABR promoted rearrangement

An efficient route for the asymmetric synthesis of α,α-disubstituted α-amino acids derivatives (1, 2, and 3) starting from readily available epoxy silyl ethers (6) has been developed. High enantiomeric purity can be realized by the present method using a combination of MABR rearrangement of a chiral epoxide and Curtius rearrangement.